362 related articles for article (PubMed ID: 22399858)
1. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
Kurtz TW; Kajiya T
Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
[TBL] [Abstract][Full Text] [Related]
2. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
3. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.
Baker WL; White WB
Ann Pharmacother; 2011 Dec; 45(12):1506-15. PubMed ID: 22116996
[TBL] [Abstract][Full Text] [Related]
4. Azilsartan medoxomil: a review of its use in hypertension.
Perry CM
Clin Drug Investig; 2012 Sep; 32(9):621-39. PubMed ID: 22877322
[TBL] [Abstract][Full Text] [Related]
5. Azilsartan medoxomil for the treatment of hypertension.
Vasiliou S
Drugs Today (Barc); 2011 Sep; 47(9):647-51. PubMed ID: 21971539
[TBL] [Abstract][Full Text] [Related]
6. Critical evaluation of the efficacy and tolerability of azilsartan.
De Caterina AR; Harper AR; Cuculi F
Vasc Health Risk Manag; 2012; 8():299-305. PubMed ID: 22661897
[TBL] [Abstract][Full Text] [Related]
7. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
8. Azilsartan: Novel Angiotensin Receptor Blocker.
Dargad RR; Parekh JD; Dargad RR; Kukrety S
J Assoc Physicians India; 2016 Mar; 64(3):96-98. PubMed ID: 27731574
[TBL] [Abstract][Full Text] [Related]
9. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
[TBL] [Abstract][Full Text] [Related]
10. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Barrios V; Escobar C
Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
[TBL] [Abstract][Full Text] [Related]
11. Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension.
Hjermitslev M; Grimm DG; Wehland M; Simonsen U; Krüger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):225-233. PubMed ID: 28444983
[TBL] [Abstract][Full Text] [Related]
12. [Azilsartan: a new angiotensin receptor blocker].
Rakugi H; Enya K
Nihon Rinsho; 2012 Sep; 70(9):1615-20. PubMed ID: 23012812
[TBL] [Abstract][Full Text] [Related]
13. [Azilsartan Medoxomil Capabilities in Arterial Hypertension and Obesity].
Vasyuk YA; Shupenina EY; Nesvetov VV; Nesterova EA; Golubkova EI
Kardiologiia; 2016 Dec; 56(11):108-112. PubMed ID: 28290827
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension.
Kamada T; Hayashi M; Fujiwara W; Yoshikawa D; Mukaide D; Sugishita Y; Yoshinaga M; Itoh T; Yokoi H; Ishii J; Watanabe E; Ozaki Y; Izawa H
Drug Chem Toxicol; 2017 Jan; 40(1):110-114. PubMed ID: 27424785
[TBL] [Abstract][Full Text] [Related]
15. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
Weber MA; White WB; Sica D; Bakris GL; Cao C; Roberts A; Kupfer S
Blood Press Monit; 2014 Apr; 19(2):90-7. PubMed ID: 24445723
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
17. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis.
Wang JG; Zhang M; Feng YQ; Ma CS; Wang TD; Zhu ZM; Kario K
J Clin Hypertens (Greenwich); 2021 May; 23(5):901-914. PubMed ID: 33609077
[TBL] [Abstract][Full Text] [Related]
18. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.
Pierini D; Anderson KV
Ann Pharmacother; 2013 May; 47(5):694-703. PubMed ID: 23585646
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.
Angeli F; Verdecchia P; Pascucci C; Poltronieri C; Reboldi G
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):379-85. PubMed ID: 23387516
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.
Shuster JE; Bleske BE; Dorsch MP
Vasc Health Risk Manag; 2012; 8():381-7. PubMed ID: 22745562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
